PNC Financial Services Group Inc. lowered its position in shares of Becton Dickinson and Co. (NYSE:BDX) by 2.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 385,133 shares of the company’s stock after selling 11,668 shares during the period. PNC Financial Services Group Inc.’s holdings in Becton Dickinson and were worth $69,220,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its stake in Becton Dickinson and by 0.5% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 31,473 shares of the company’s stock valued at $5,338,000 after buying an additional 150 shares during the last quarter. Quotient Investors LLC boosted its stake in Becton Dickinson and by 99.9% in the second quarter. Quotient Investors LLC now owns 7,583 shares of the company’s stock valued at $1,286,000 after buying an additional 3,790 shares during the last quarter. Gulf International Bank UK Ltd boosted its position in shares of Becton Dickinson and by 4.8% in the second quarter. Gulf International Bank UK Ltd now owns 65,007 shares of the company’s stock worth $11,024,000 after buying an additional 3,000 shares in the last quarter. Central Bank & Trust Co. boosted its position in shares of Becton Dickinson and by 7.9% in the second quarter. Central Bank & Trust Co. now owns 9,049 shares of the company’s stock worth $1,535,000 after buying an additional 662 shares in the last quarter. Finally, Bank of Stockton boosted its position in shares of Becton Dickinson and by 6.3% in the second quarter. Bank of Stockton now owns 5,944 shares of the company’s stock worth $1,008,000 after buying an additional 350 shares in the last quarter. Institutional investors own 81.35% of the company’s stock.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Shares of Becton Dickinson and Co. (NYSE:BDX) opened at 170.31 on Tuesday. The firm’s 50-day moving average is $171.40 and its 200-day moving average is $172.45. Becton Dickinson and Co. has a 12-month low of $129.50 and a 12-month high of $181.76. The firm has a market cap of $36.16 billion, a price-to-earnings ratio of 37.93 and a beta of 1.04.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 3rd. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.09 by $0.03. The firm earned $3.23 billion during the quarter, compared to the consensus estimate of $3.22 billion. Becton Dickinson and had a net margin of 7.82% and a return on equity of 24.45%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.94 EPS. Analysts predict that Becton Dickinson and Co. will post $9.52 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 30th. Shareholders of record on Friday, December 9th will be issued a $0.73 dividend. The ex-dividend date is Wednesday, December 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.71%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.66. Becton Dickinson and’s payout ratio is currently 58.54%.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Daily Political and is the propert of of Daily Political. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international copyright & trademark laws. The legal version of this story can be read at http://www.dailypolitical.com/2016/11/29/pnc-financial-services-group-inc-decreases-stake-in-becton-dickinson-and-co-bdx.html.

A number of research analysts have commented on BDX shares. Citigroup Inc. cut shares of Becton Dickinson and from a “neutral” rating to a “sell” rating and cut their price target for the stock from $167.00 to $165.00 in a research note on Friday, September 23rd. Cowen and Company restated an “outperform” rating and set a $185.00 price target on shares of Becton Dickinson and in a research note on Tuesday, August 16th. Leerink Swann restated a “market perform” rating and set a $185.00 price target (up previously from $180.00) on shares of Becton Dickinson and in a research note on Monday, November 21st. Jefferies Group restated a “buy” rating on shares of Becton Dickinson and in a research note on Friday, August 5th. Finally, Zacks Investment Research cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Wednesday, November 16th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Becton Dickinson and presently has an average rating of “Buy” and an average price target of $175.65.

In other news, insider Linda M. Tharby sold 11,704 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $177.27, for a total transaction of $2,074,768.08. Following the completion of the sale, the insider now owns 22,146 shares of the company’s stock, valued at approximately $3,925,821.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Stephen Sichak sold 10,352 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $176.10, for a total transaction of $1,822,987.20. Following the sale, the insider now directly owns 26,892 shares of the company’s stock, valued at approximately $4,735,681.20. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

5 Day Chart for NYSE:BDX

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co. (NYSE:BDX).

Receive News & Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related companies with MarketBeat.com's FREE daily email newsletter.